On November 6, 2020 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, reported that it is hosting a Virtual R&D Day today (Press release, BerGenBio, NOV 6, 2020, View Source [SID1234570917]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The online event will begin at 13.00pm CET (04.00am PST/06.00am CST). Please click here to register.

The event will feature experts from academic institutions across Europe and the US, highlighting the role of AXL kinase as an essential mediator of the biological mechanisms underlying life-threatening diseases, such as cancer, fibrosis and infectious diseases, including COVID-19.

Each presentation will be followed by a Q&A session. Further details on the presentations can be found in the agenda below.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "BerGenBio has always been committed to pursuing excellence and innovation in R&D.We remain a world leader in understanding the role and function of AXL biology, and with our collaborators we have demonstrated that AXL is a key driver of immune evasive and drug-resistant metastatic cancer, as well as other aggressive diseases. We are grateful to all our speakers, who during today’s event will beproviding insights into the latest AXL research, including the clinical benefit seen from bemcentinib."